Our in vitro results recommend that EAM-2201 must be examined concerning potential in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 things to do and aggressive inhibition of UGT1A3 action. Dose-response outcomes of subcutaneously administered AM-2201 on entire body temperatures and catalepsy scores in… https://asenacau515csh9.wikijm.com/user